Motivity, a provider of clinical SaaS solutions for Applied Behavior Analysis (ABA) providers who treat children with autism, announced a $27 million investment from Five Elms Capital. This funding enables Motivity to accelerate product innovation, expand its team, and strengthen support for ABA providers worldwide.
Since its founding in 2012, Motivity’s mission has been to empower ABA clinicians with cutting-edge technology that strengthens clinical effectiveness and improves outcomes. To date, the company secured $11 million in Small Business Innovative Research (SBIR) grants used to develop next-generation solutions, including AI-driven workflows, analytics for clinical decision support, and caregiver engagement tools. Today, Motivity serves over 550 organizations across seven countries, enhancing the delivery of high-quality and data-driven care.
The partnership with Five Elms marks a major milestone in Motivity’s growth. And after evaluating multiple capital partners, Motivity selected Five Elms for its deep experience scaling founder-led software companies without compromising product integrity or customer service.
With 38 active portfolio companies and a team of over 75 professionals, Five Elms brings strategic operational expertise along with the capital investment to support Motivity’s long-term vision. And together, the teams plan to accelerate advancements in Motivity’s technology, expand customer support, and enhance Motivity’s ability to serve ABA organizations at every level.
As Motivity enters the next phase, the company’s leadership is evolving to drive future expansion. And founder Rex Jakobovits, PhD, will transition to Chief of Strategy and Innovation, utilizing his expertise to guide the company’s long-term vision and technological direction.
Joining the team as CEO is Smith Anderson, previously an Operator with Five Elms Capital, who brings extensive experience in scaling technology companies. And this leadership transition ensures a blend of innovative vision and operational expertise. Motivity’s existing team remains fully intact, providing customers with operational continuity and maintaining the momentum of the platform’s ongoing development.
Motivity will expand its R&D efforts, focusing on AI-driven insights, advanced clinical decision-support tools, and solutions to strengthen caregiver engagement. And the company will enhance its enterprise capabilities to meet the evolving needs of larger ABA organizations.
KEY QUOTES:
“This investment isn’t just about scaling; it’s about pushing the boundaries of what’s possible in ABA technology. Our focus remains the same: delivering intuitive, intelligent solutions that help providers focus on what matters most – improving the lives of children with autism and their families. We couldn’t have gotten here without SBIR funding from the National Institute of Mental Health and the support of its business development programs, including the NIH Entrepreneur in Residence consultation and the NIH Company Showcase Program. With Five Elms’ partnership, we can accelerate our capacity to innovate and expand our impact.”
- Rex Jakobovits, Founder of Motivity
“Motivity is a unique company, transforming the day-to-day lives of ABA practitioners and patients alike through relentless product innovation and a mission-driven culture. We are thrilled to partner with the Motivity team to continue to scale the business, expand the platform, and improve outcomes for customers and patients.”
- Austin Gideon, Principal at Five Elms Capital, who will join the Motivity board of directors as part of the investment
“Motivity remains focused on clinical outcomes. This investment empowers us to expand that mission with enhanced tools, greater scale, and even stronger support. Our dedication to innovation and customer care remains unwavering. We are excited about the opportunities ahead and deeply committed to equipping ABA providers with best-in-class tools to deliver life-changing care.”
- Smith Anderson
“Motivity’s team is now well-positioned to grow alongside our customers. We now have the rocket fuel to expand our reach, refine our solutions, and ensure that more organizations can benefit from the clinical excellence that we bring to the industry.”
- Chief Clinical Officer Emaley McCulloch
